A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Key facts

Sponsor

BeiGene

Principal Investigator

Study Director

BeiGene

Intervention

BGB-45035(drug)

Enrollment

90 target

Eligibility

18 years · All sexes

Timeline

2025 – 2026

Study locations (29)

• The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
• Anhui Provincial Hospital, Hefei, Anhui, China
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
• The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, China
• Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
• The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
• Nanyang Central Hospital, Nanyang, Henan, China
• Zhengzhou Central Hospital, Zhengzhou, Henan, China
• The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
• Chenzhou No1 Peoples Hospital, Chenzhou, Hunan, China
• +14 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07137598
  A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
  Hoffmann-La Roche
• RECRUITINGPHASE1NCT07200596
  The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
  Guangdong Hengrui Pharmaceutical Co., Ltd
• RECRUITINGNANCT07089381
  Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
  Ain Shams University
• RECRUITINGPHASE1NCT07040930
  Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
  Changchun GeneScience Pharmaceutical Co., Ltd.
• RECRUITINGNANCT06693479
  Could a Feedback Device Help Manage Work-related Shoulder Disorders?
  Laval University
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06475495
  Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
  Charite University, Berlin, Germany
• RECRUITINGNCT07315997
  The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
  Brigham and Women's Hospital
• RECRUITINGNCT07463937
  A RWS of SC MTX in Chinese RA Patients
  Peking University People's Hospital

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis →